MedPath
Found 58 clinical trials|View Analysis
Sort by:

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

First Posted Date
2020-08-14
Last Posted Date
2024-12-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
757
Registration Number
NCT04513912
Locations
🇨🇿

A Shine S R O, Plzen, Czechia

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

SW Biomedical Research LLC, Tucson, Arizona, United States

and more 166 locations

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

First Posted Date
2020-04-08
Last Posted Date
2023-10-24
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
676
Registration Number
NCT04338321
Locations
🇩🇪

Universitatsklinikum Jena, Jena, Germany

🇵🇱

Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Poland

🇵🇹

Fund. Champalimaud, Lisboa, Portugal

and more 165 locations

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: SEP363856
Drug: quetiapine XR
First Posted Date
2019-10-04
Last Posted Date
2024-06-28
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
475
Registration Number
NCT04115319
Locations
🇷🇴

Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia", Sectia Psihiatrie XII, Bucuresti, Romania

🇷🇺

Saint Petersburg State Budgetary Institution of Healthcare "Psychoneurological Dispensay No 1", Saint Petersburg, Russian Federation

🇷🇺

State Budgetary Institution of Healthcare of Stavropol territory "Regional Specialization Psychiatry Hospital # 2", Stavropol, Russian Federation

and more 43 locations

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2018-03-14
Last Posted Date
2023-02-08
Lead Sponsor
Bukwang Pharmaceutical
Target Recruit Count
210
Registration Number
NCT03465787
Locations
🇰🇷

Borame Medical Center, Seoul, Seoul, Dongjak-gu, Korea, Republic of

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Phase 2
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Quetiapine XR
Drug: JNJ-42847922
Drug: Placebo Matching to JNJ-42847922
Drug: Placebo Matching to Quetiapine XR
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)
Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
First Posted Date
2017-10-25
Last Posted Date
2023-05-03
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
107
Registration Number
NCT03321526
Locations
🇺🇸

Hapworth Psychiatric Medical PLLC, New York, New York, United States

🇺🇸

Suburban Clinical Research Group, Inc, Bolingbrook, Illinois, United States

🇺🇸

Ericksen Research and Development, Clinton, Utah, United States

and more 47 locations

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Phase 4
Completed
Conditions
Depressive Disorder, Major
Interventions
First Posted Date
2017-07-02
Last Posted Date
2019-12-04
Lead Sponsor
University of Saskatchewan
Target Recruit Count
1790
Registration Number
NCT03207438

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Phase 1
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: Lu AF35700 (10 mg/day)
Drug: Lu AF35700 (30 mg/day)
Drug: Quetiapine (Seroquel XR® 800 mg/day)
First Posted Date
2016-09-15
Last Posted Date
2019-09-12
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
119
Registration Number
NCT02901587
Locations
🇺🇸

US1104, Long Beach, California, United States

The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Administration of quetiapine XR
First Posted Date
2014-05-20
Last Posted Date
2014-05-20
Lead Sponsor
Tri-Service General Hospital
Target Recruit Count
61
Registration Number
NCT02142556
Locations
🇨🇳

Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2014-05-07
Last Posted Date
2014-05-07
Lead Sponsor
University of Calgary
Target Recruit Count
57
Registration Number
NCT02132286
Locations
🇨🇦

University of Calgary: Foothills medical centre, Calgary, Alberta, Canada

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

Not Applicable
Completed
Conditions
Generalized Anxiety Disorder
Major Depressive Disorder
Interventions
Drug: seroquel xr
Behavioral: CBT
First Posted Date
2013-10-29
Last Posted Date
2018-02-15
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
62
Registration Number
NCT01971203
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath